HURA:NASDAQTuHURA Biosciences, Inc. Analysis

TuHURA Biosciences (HURA) trades at $2.19, hovering just above the computed support of $1.89 and well below the near‑term resistance of $2.79. The 20‑day SMA ($2.28) sits slightly above the current price, while the 50‑day SMA ($2.31) is higher still, indicating modest upside pressure, yet the 200‑day SMA ($1.88) is below price, suggesting a long‑term neutral bias. Technical momentum is mixed: RSI is at 48 (near the midpoint), but the MACD histogram is negative and the signal line is labeled bearish, and volume trends are decreasing. Fundamentally, the company has no revenue, negative earnings (trailing EPS –$0.61), a high price‑to‑book ratio of 6.1, and a beta of 3.44, reflecting extreme price volatility (30‑day volatility ~82%). The balance sheet shows $6.3 M cash against $0.46 M debt, bolstered by a $50 M loan facility that management says will fund operations to 2028, and the firm recently regained Nasdaq compliance with a $1.00 minimum bid price. Recent news highlights the Q1 2026 results, the loan runway, and progress toward a Phase 3 trial of its lead immuno‑oncology candidate, which could be a catalyst if successful.